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HIV infection is characterized by gradual immune
system collapse and hematopoietic dysfunction.
We recently showed that HIV enters multipotent
hematopoietic progenitor cells and establishes both
active cytotoxic and latent infections that can be
reactivated by myeloid differentiation. However,
whether these multipotent progenitors include long-
lived hematopoietic stem cells (HSCs) that could
establish viral reservoirs for the life of the infected
person remains unknown. Here we provide direct
evidence that HIV targets long-lived HSCs and show
that infected HSCs yield stable, multilineage engraft-
ment in a xenograftmodel. Furthermore, we establish
that the capacity to use the chemokine receptor
CXCR4 for entry determineswhether a virus will enter
multipotent versus differentiated progenitor cells.
Because HSCs live for the life span of the infected
person and are crucial for hematopoietic health,
these data may explain the poor prognosis associ-
ated with CXCR4-tropic HIV infection and suggest
HSCs as long-lived cellular reservoirs of latent HIV.
INTRODUCTION
The natural course of HIV disease is characterized by progres-
sive destruction of the host immune system, manifested as
a decline in CD4+ T cell counts over several years. Depletion of
CD4+ T cells invariably causes an immunocompromised state
in the host, leading to the onset of AIDS and ultimately death
from opportunistic infections. Despite extensive study, the exact
mechanisms triggering the progression to AIDS remain unclear.Cell HoHIV entry into permissive cells is mediated by interactions of
the HIV envelope (Env) protein with CD4 and a chemokine core-
ceptor (CCR5 or CXCR4 [Alkhatib et al., 1996; Deng et al., 1996;
Dragic et al., 1996; Feng et al., 1996]). Initial transmission is
mediated primarily by CCR5-utilizing (R5-tropic) HIV (Lathey
et al., 1999; van’t Wout et al., 1994), and R5-tropic isolates are
more commonly detected early in the disease (reviewed in
Margolis and Shattock, 2006), but eventually CXCR4-utilizing
(X4-tropic) isolates predominate in most infected individuals
(Richman and Bozzette, 1994; Shankarappa et al., 1999). The
conversion of HIV Env from R5-tropic to X4-tropic requires
only a small number of changes in the Env V3 region. This
conversion has been associated with more rapid disease
progression manifested as reduced CD4+ T cell counts and
a poor clinical prognosis (Connor et al., 1997; Daar et al., 2007;
Karlsson et al., 1994; Scarlatti et al., 1997; Schuitemaker et al.,
1992; Shepherd et al., 2008; Waters et al., 2008; Weiser et al.,
2008; Yu et al., 1998; Zhou et al., 2008). Furthermore, in the
rare instances when infection is initiated by dual (R5X4) or
X4-tropic HIV, CD4 counts decline rapidly, and disease progres-
sion is sometimes accelerated (Sheppard et al., 2002; Yu et al.,
1998). It is not clear whether the conversion to CXCR4-tropic
virus plays a causal role in disease progression or whether other
factors account for this association.
CD4+ T cells, myeloid cells, and subsets of HSPCs express
HIV receptors (CD4 [Morrison and Weissman, 1994] and CCR5
or CXCR4 [Carter et al., 2010; Ishii et al., 1999; Majka et al.,
1999; Peled et al., 1999; Shen et al., 1999; Viardot et al.,
1998]), but whether HSPCs can be infected has been controver-
sial in the literature (Folks et al., 1988; Redd et al., 2007; Shen
et al., 1999; Stanley et al., 1992; Zhang et al., 2007), and there
is evidence that these cellsmay be relatively resistant to infection
(Shen et al., 1999; Zhang et al., 2007). Recent reports indicate
that low-level infection of multipotent HSPCs occurs in vivo
and in vitro (Carter et al., 2010; Redd et al., 2007), but active
infection is cytotoxic and hard to detect in long-term culturest & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevier Inc. 223
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Patient
Identifier
Year of
diagnosis
CD4
count
WBC
(X103/mm3)
RBC
(X106/mm3)
Platelets
(X103/mm3)
A1 1986 41 2.0 4.75 1032.3
1 2006 840 5.1 4.41 1738.0
A2 1990 109 4.6 5.4 2031.8
A3 1994 540 7.0 5.48 1613.0
2 1998 239 4.7 4.52 1338.5
3 2008 504 4.3 5.38 1449.0
4 1999 298 4.3 4.24 754.0
5 2009 364 7.6 4.85 29528.0
6 2005 164 5.0 5.31 11213.2
BMMC counts
(X107/10cc)
7 2006 705 7.6 4.93 1805.2
8 1997 292 9.4 3.89 2515.0
9 2004 263 6.1 4.64 1766.6
10 2001 533 4.6 4.96 2475.4
11 1987 447 4.5 3.56 2983.6
12 2002 537 7.1 4.15 1798.8
13 1984 612 5.8 5.19 1925.1
14 2006 647 4.5 4.63 2892.4
15 2001 912 5.8 4.59 26810.0
16 1995 282 7.0 4.52 1543.3
A Figure 1. Total Number of Bone Marrow
Mononuclear Cells Is Correlated with Year
of Diagnosis in HIV+ Donors with High Viral
Loads
(A) Complete blood count of HIV+ donors with
high viral loads (1–6 and A1–A3, 61,000–
202,000 copies/ml) and low viral loads (7–16,
<48 copies/ml).
(B) The number of purified bone marrow cells
versus year of diagnosis for high-viral-load
donors.
(C) CD4 counts of high-viral-load donors at the
time of bone marrow aspiration plotted as a func-
tion of year of diagnosis.
(D) As (B), but with an outlier with a high mononu-
clear cell yield (Donor 5) removed.
(E) The number of purified bone marrow cells
versus year of diagnosis for low-viral-load donors.
(F) CD4 counts of low-viral-load donors at the time
of bone marrow aspiration plotted as a function of
year of diagnosis.
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CXCR4-Tropic HIV Infects Hematopoietic Stem Cells(Carter et al., 2010). Importantly, the assays used in these studies
could not distinguish whether infected cells were long-lived
hematopoietic stem cells (HSCs) or short-lived commonmyeloid
progenitor cells. Thus, it is still unknown whether HIV infects
HSCs, a subset of HSPCs defined by their ability to stably engraft
and generate multiple lineages upon transplantation into immu-
nocompromised mice. The distinction between HSCs and other
multipotent hematopoietic progenitor cells (HPCs) is of key
importance, as infection of the long-lived HSC population would
have a greater impact on hematopoiesis and this population
would have greater potential to serve as a long-term reservoir
of HIV in infected people.
In this study, we provide evidence that HIV Envs can target
HSCs and that integration can occur within these cells. More-
over, we show that HIV Env tropism influences which subset(s)
of HSPCs is infected: only CXCR4-tropic envelopes permit entry
into multipotent HSPCs, including HSCs. These findings suggest
not only that HSCs can become infected by HIV and thus have
the potential to serve as a long-term reservoir of virus, but also
that the association between the emergence of CXCR4-tropic
isolates and declining CD4+ T cell counts could be related to
infection of multipotent HSPCs.
RESULTS
Recent work has indicated that bone marrow CD34+ HSPCs
from HIV+ donors are targets of HIV infection in vivo (Carter
et al., 2010). In this study, three of six donors with high viral loads
had evidence of active HIV infection of bone marrow CD34+
cells. In the remaining three donors, active infection could be
induced by culturing the cells in GM-CSF and TNF-a (Carter
et al., 2010). However, CD34+ cells are a heterogeneous popula-
tion, and it is not known whether stem cells or multipotent
progenitor cells are infected in HIV+ people. Healthy stem cells
and multipotent progenitor cells are needed to maintain all
hematopoietic lineages as well as normal bone marrow cellu-224 Cell Host & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevierlarity. Thus, it is expected that infection of primitive HSPCs by
HIV would eventually be reflected in a loss of total bone marrow
mononuclear cells. To examine this, we quantified the bone
marrow cellularity of high-viral-load (>50,000 copies/ml) donors
(Carter et al., 2010) who had relatively normal complete white
blood cell counts (Figure 1A). Interestingly, we found a striking
correlation between the number of mononuclear cells isolated
from 10 ml of aspirate and the year of diagnosis (Figure 1B).
This correlation was more significant in our cohort (p < 0.03)
than the correlation between CD4 cell count and year of diag-
nosis (p = 0.12) (Figure 1C) and was significant even when an
outlier with a very high cell count was excluded (p < 0.02) (Fig-
ure 1D). A second cohort of patients with undetectable (<48
copies/ml) viral loads on highly active antiviral therapy (HAART)
was also studied (Figure 1A). In this group, HIV genomes could
be detected within CD34+ cells from 40% of donors, but Gag
expression was only detectable after culturing the cells in GM-
CSF and TNF-a, consistent with latent infection of this cell type
(Carter et al., 2010). In this group, we observed no correlation
between bone marrow cellularity and year of diagnosis (Fig-
ure 1E) or between CD4 cell count and year of diagnosis (Fig-
ure 1F). These data provide in vivo support for a potent effect
of HIV on the bone marrow, which requires active viral replica-
tion. While this effect may be due to the chronic inflammation
associated with unsuppressed HIV replication, it is also consis-
tent with direct infection of multipotent HSPCs by HIV.
X4-Tropic Envs Infect Multipotent HSPCs
The conversion of HIV Env from R5-tropic to X4-tropic is associ-
ated with more rapid disease progression manifested as
reduced CD4+ T cell counts and a poor clinical prognosis (Con-
nor et al., 1997; Daar et al., 2007; Karlsson et al., 1994; Scarlatti
et al., 1997; Schuitemaker et al., 1992; Shepherd et al., 2008;
Waters et al., 2008; Weiser et al., 2008; Yu et al., 1998; Zhou
et al., 2008). To determine whether chemokine receptor expres-
sion influences the type of HSPC infected by HIV, we testedInc.
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Figure 2. CXCR4-Tropic HIV Envs Infect CD133+,
CD34+ HSPCs
(A) Schematic of HIV-7SF-GFP construct and generic
HIV envelope plasmid used to construct viruses used in
(B)– (D).
(B and C) Flow cytometric analysis of cord-blood-derived
CD133+ cells infected with a minimal HIV (HIV-7SF-GFP
[Yam et al., 2002]) that lacked expression of HIV gene
products and was pseudotyped with the indicated HIV
Env. In this construct, GFP is expressed from a heterolo-
gous promoter (Yam et al., 2002). Cells were analyzed
3 days postinfection. The left panels show the GFP+
gating. These events were overlaid in green on the right
plots, which also show staining of the total cell population
in gray. Isotype control staining is shown in the top panel.
The percentage of GFP+ cells that were CD34HighCD133+
is shown in the upper right-hand corner.
(D) Summary plot of HIV-1 Env data. Results are compiled
from ten experiments with CCR5-tropic Env proteins
(94UG114.1.6, eight replicates; YU-2, one experiment;
ZM53M.PB12, one experiment) and 16 experiments with
CXCR4 and dual-tropic Env proteins (HXB2, eight repli-
cates; 89.6, seven replicates; 92HT593, one experiment);
error bars are standard error of the mean. ***p < 0.0001.
(E) Upper panel, schematic of full-length HIV used in lower
panel. Lower panel, flow cytometric analysis of cord-
blood-derived CD133+ cells 3 days postinfection with
full-length, wild-type HIVs. NL4-3 has an X4-tropic Env
and 94UG114.1.6 has an R5-tropic Env. Gag+ cells were
gated in the left panels, and these events (red dots) were
overlaid on CD34 versus CD133 plots in the right panels
to determine the immunophenotype of the infected cells
compared with the total cell population (gray dots). Iso-
type control staining is shown in the top panel. The
percentage of Gag+ cells that were CD34+CD133+ is
shown in the upper right-hand corner. See also Figure S1.
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CXCR4-Tropic HIV Infects Hematopoietic Stem Cellsa panel of HIVs differing only in the Env they contained. These
virus particles were generated by cotransfecting aGFP-express-
ing, replication-defective, minimal HIV construct (HIV-7SF-GFP,
Figure 2A) (Yam et al., 2002), which expresses GFP but no HIV
proteins, along with a packaging-null/env-null HIV genome and
anHIV Env-expressing plasmid (Carter et al., 2010). The resulting
virus particles thus contain unmodified HIV proteins, including
Env, integrase, and reverse transcriptase. Once the HIV genome
is integrated into the genome of the target cell, however, newHIV
proteins are not transcribed, and instead GFP is expressed from
the constitutively active spleen focus-forming virus (SFFV)
promoter. These viral supernatants were used to infect HSPCs
isolated by magnetic sorting. After infection, the cell surface
phenotype of GFP+ cells was determined by flow cytometry.Cell Host & Microbe 9, 2Remarkably, we found that both the X4-tropic
Env HXB and the R5X4-tropic Env 89.6 were
able to target various cell types, including
cells with a surface phenotype consistent with
multipotent HSPCs (CD34HighCD133+) (Figures
2B and 2C). Infection occurred both when the
cells were infected by spin infection and
when cells were pulsed with virus for 2h at
37C (Figure S1). In contrast, the R5-tropic
Envs YU-2 (Figure 2B, lower panel) and
ZM53M.PB12 (Figure 2C, lower panel) infectedCD34HighCD133+ cells inefficiently; most infection was seen in
cells with a surface phenotype consistent with less primitive cells
(CD34LowCD133). Similar results were observed in ten replicate
experiments using three different CCR5-tropic Envs and 16
replicates using three different CXCR4- or dual-tropic Envs
(summarized in Figure 2D).
We performed additional experiments using full-length
HIVs encoding CXCR4-tropic Env (NL4-3) or CCR5-tropic
Env (94UG114.1.6), except that in these cases we detected
infection by expression of intracellular Gag. As shown in Fig-
ure 2E, we again found that CXCR4-tropic NL4-3 was able to
infect cells with a surface phenotype consistent with HSPCs
(CD34HighCD133+). In contrast, CCR5-tropic 94UG114.1.6 only
infected cells with a surface phenotype consistent with less23–234, March 17, 2011 ª2011 Elsevier Inc. 225
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94UG114.1.6 R5 - -Primary
BaL.01 R5 ND +/-Lab-adapted
X4HXB2 +++ +++Lab-adapted
CD34+CD133+ Colony Formation
ZM53M.PB12 R5 +/- NDPrimary
Table 1. Summary of HIV envelopes and their phenotypes.
Type
F
A
Figure 3. CXCR4-Tropic HIV Envs Infect HSPCs with the Capacity to Form Multilineage Colonies
(A) Schematic of HIV-7SF-GFP construct and generic HIV envelope plasmid used to construct viruses used in (B)– (E).
(B) Flow cytometric analysis of cord-blood-derived CD133+ cells infected with HIV-7SF-GFP pseudotyped with HXB (X4-tropic) or YU2 (R5-tropic) Env proteins
and purified by flow sorting.
(C) Example colonies identified after culturing cells isolated as shown in (B) for 14 days. Phase contrast and epifluorescence microscopy are shown (erythroid,
CFU-E; myeloid, CFU-GM; or multilineage, CFU-GEMM).
(D) Quantification of colony formation for the experiment shown in (C) and for two similar experiments using other HIV Envs, as indicated (erythroid, CFU-E;
myeloid, CFU-GM; or multilineage, CFU-GEMM). The total number of colonies from six replicate wells is displayed.
(E) Summary of colony formation results. Data were compiled from five independent experiments using six different Env proteins. The average normalized number
of colonies observed with CXCR4- or dual-tropic Env versus CCR5-tropic Env is depicted. Error bars represent standard deviation and p values were determined
using the two-tailed Student’s t test (erythroid, CFU-E; myeloid, CFU-GM; or multilineage, CFU-GEMM).
(F) Summary table of the ability of HIV-1 Envs of different tropism to infect CD133+CD34High and multipotent HSPCs.
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CXCR4-Tropic HIV Infects Hematopoietic Stem Cellsprimitive cells (CD34LowCD133) (Figure 2E). Collectively, these
findings indicate that wild-type X4- and R5-tropic HIVs target
distinct subsets of HSPCs and that X4-tropic viruses have an
increased capacity to target cells with surface markers charac-
teristic of multipotent HSPCs.
X4-Tropic HIVs Infect Multipotent HSPC
To test whether X4-tropic HIVs were capable of infecting multi-
potent HSPCs, we asked whether the targeted cells formed
multilineage colonies in culture. For these experiments, cord-
blood-derived HSPCs were infected with HIV-7SF-GFP, pseu-
dotyped with HXB Env (X4-tropic) or YU-2 Env (R5-tropic)
(Figure 3A). The use of this construct was critical for these exper-
iments because wild-type HIV kills actively infected HSPCs226 Cell Host & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevierwithin a few days (Carter et al., 2010), making it difficult to deter-
mine the developmental capacity of the targeted cell type by
colony formation, as this assay takes weeks.
Three days after infection with HIV-7SF-GFP, the GFP+ cells
were purified (>95% pure) (Figure 3B), and 6000 GFP+ cells
from each infection were plated in methylcellulose medium.
After 2 weeks, colonies were analyzed for morphology and
GFP expression. We found 140 erythroid (CFU-E), 158 myeloid
(CFU-GM), and 30 multilineage (CFU-GEMM) colonies gener-
ated from cells infected with HXB enveloped virus (Figures 3C
and 3D). CFU-GEMM colonies form only fromHSCs, multipotent
progenitor cells, and common myeloid progenitors, indicating
that the HXB Env permitted entry into one of these immature
HSPC types. In contrast, HSPCs infected with YU-2-envelopedInc.
Cell Host & Microbe
CXCR4-Tropic HIV Infects Hematopoietic Stem Cellsvirus gave rise to about 10-fold fewer colonies, primarily small
granulocyte/macrophage colonies (total of 14 CFU-E, 23 CFU-
GM, and 3 CFU-GEMM) (Figures 3C and 3D).
To determine whether the capacity to infect multipotent
HSPCs was consistently associated with chemokine receptor
use, we analyzed additional Envs (Figure 3D). In each case,
we found X4 tropism or dual tropism (NL4-3 and 92HT593) asso-
ciated with infection of cells able to generate multilineage
colonies. In contrast, cells infected using R5-tropic Env (BaL
and 94UG114.1.6) largely lacked this capacity; we observed
only two CFU-GEMM colonies generated from cells infected
with HIV-7SF-GFP pseudotyped with BaL Env and none from
cells infected using 94UG114.1.6 Env (Figures 3D–3F). These
findings demonstrate that X4-tropic Envs have the capacity to
infect multipotent HSPCs, whereas R5-tropic Envs primarily
infect more mature HSPCs.
CD4 and CXCR4 Receptor Use Is Required for Infection
of Primitive HSPCs
We hypothesized that infection of primitive HSPCs with X4-
tropic Envs occurred by the canonical mechanism, wherein
HIV Env triggers membrane fusion after binding CD4 and
CXCR4 on the target cell. While this is the most common
scenario, numerous reports have documented HIV infection by
CD4-independent mechanisms, usually involving the use of
CXCR4 alone to facilitate entry (Endres et al., 1996; Hoxie
et al., 1998; Liu et al., 2004; Saha et al., 2005; Zerhouni et al.,
2004). To explore this possibility, we treated cord-blood-derived
HSPCs and CEM T cells with the CD4-blocking antibody L3T4
before infecting the cells with HIV-7SF-GFP pseudotyped with
the dual-tropic 89.6 Env. As expected, pretreatment with CD4-
blocking antibody substantially reduced infection of CEM
T cells (Figure 4A). Pretreatment of HSPCs with CD4-blocking
antibody inhibited infection even more robustly, causing a
near-complete block in infection (Figure 4A). These data demon-
strate that infection of HSPCs is strictly dependent on CD4.
Moreover, CD4 antibody treatment blocked infection of all cells
tested, those with a surface phenotype consistent with primitive
HSPCs (CD34HighCD133+) as well as more mature progenitors,
suggesting that infection of all HSPCs is CD4 dependent
(Figure 4B).
As described above, infection ofmultipotent HSPCsby various
HIVs correlates with their capacity to use CXCR4 for entry
(Figure 3). These data likely reflect the relative expression of
chemokine receptors on multipotent HSPCs (i.e., that CXCR4 is
more widely expressed on multipotent HSPCs than is CCR5)
(Carter et al., 2010). Less likely possibilities were that somemulti-
potent HSPCs express both chemokine receptors but that the
X4-tropic Env is required for another function other than entry
or that signaling through CXCR4 is required for productive infec-
tion. To distinguish these possibilities, we asked whether
blockadeofCXCR4would reduce infectionofmultipotentHSPCs
by dual-tropic HIV Envs. We tested this approach using two
related T cell lines: CEM-SS, which expresses only CXCR4, and
CEM-R5, which expresses both CXCR4 and CCR5. These cells
were treated with the small molecule CXCR4 antagonist
AMD3100 (Donzella et al., 1998) and infected with HIV-7SF-GFP
pseudotyped with the dual-tropic Env 92HT593. As expected,
AMD3100 blocked infection of CEM-SS cells almost completelyCell Hobut only partially blocked infection of CEM-R5 cells, demon-
strating use of CCR5 by 92HT593 Env in these cells (Figure 4C).
We then treated cord-blood-derived HSPCs with AMD3100 or
maraviroc (CCR5-blocking) and infected the cells with HIV-7SF-
GFP pseudotyped with 89.6 Env. We found that not only did
AMD3100 reduce the rate of infection in total HSPCs, it nearly
eliminated infection of CD34HighCD133+ cells (Figure 4D). By
contrast, maraviroc did not impede infection of CD34HighCD133+
cells by 89.6-pseudotyped HIV-7SF-GFP (Figure 4D) but did
eliminate infection of HSPCs when we used the R5-tropic Env
YU-2 (Figure 4E). We further observed that when we infected
HSPCs with HIV-7SF-GFP pseudotyped with 92HT593 Env,
treatment with AMD3100 reduced overall infection rates in
CD34HighCD133+ cells to rates comparable to those observed
with the R5-tropic 94UG Env (Figure 4F). Consistent with these
results, we observed that CD34HighCD133+ HSPCs expressed
CXCR4 at higher levels than CCR5 (Figures 4G and 4H). We
confirmed the low levels of CCR5 on these cells functionally
with a calcium flux assay to assess response to CXCR4 and
CCR5 ligands (Figures S2A and S2B) and with an acid wash to
confirm that bound ligand was not masking CCR5 on these cells
(Figure S2C). Finally, to assess whether crosslinking of CXCR4
could permit entry by CCR5-tropic virus, we infected CD133+
HSPCs with HIV-7SF-GFP pseudotyped with YU-2 Env in the
presence or absence of full-length NL4-3. We then examined
GFP expression in the infected populations to determine which
cell types were infected by the R5-tropic virus and found that
NL4-3 did not permit the CCR5-tropic virus to enter CD133+ cells
(Figure S2D).
Next, we treated cord-blood-derived HSPCs with AMD3100
or maraviroc and infected themwith HIV-7SF-GFP pseudotyped
with dual-tropic 89.6 Env. We sorted GFP+ cells from AMD3100-
treated, maraviroc-treated, and control-treated cultures and
plated the cells in methylcellulose medium. Infected control-
treated and maraviroc-treated cells formed numerous erythroid,
myeloid, andmultilineage colonies (Figure 5A), whereas infection
of AMD3100-treated colony-forming cells was dramatically
reduced (Figure 5B). Treatment with maraviroc (Figure 5C) or
AMD3100 (Figure 5D) had no effect on colony formation by unin-
fected cells. These data show that CXCR4 usage is necessary for
the infection of multipotent HSPCs by HIV and that CCR5 cannot
substitute.
X4-Tropic HIVs Infect HSCs Capable of Multilineage
Reconstitution of Immunocompromised Mice
Having demonstrated that HIV can infect multipotent HSPCs,
we next asked whether HIV could infect HSCs capable of
stably engrafting irradiated NOD/SCID IL-2Rgnull mice. Stable
multilineage reconstitution in immunocompromised mice can
be accomplished only by engraftment of HSCs, and thus this is
a definitive assay for infection of HSCs (Christensen and Weiss-
man, 2001; Jones et al., 1990; Osawa et al., 1996; Uchida and
Weissman, 1992). Because we observed little infection of multi-
potent HSPCs with R5-tropic HIV Envs, we used only X4-tropic
Env for these experiments. We infected purified CD133+ cells
with HIV-7SF-GFP, pseudotyped with X4-tropic HXB Env (Fig-
ure 6A, upper panel). Three days after infection, GFP+ cells
were enriched to 40%–70% purity (Figure 6A, lower panel) and
intrafemorally injected into sublethally irradiated NOD/SCIDst & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevier Inc. 227
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Figure 4. Infection of CD34HighCD133+ HSPCs Is Dependent on CD4 and CXCR4
(A) Flow cytometric analysis of cord-blood-derived CD133+ HSPCs or CEM T cells preincubated with anti-CD4 antibody (L3T4, 20 mg/ml) or control antibody and
then infected with HIV-7SF-GFP pseudotyped with 89.6 Env. The cells were analyzed 3 days postinfection. The numbers in the right panels are fold inhibition of
infection.
(B) Flow cytometric analysis of cord-blood-derived CD133+HSPCs preincubatedwith control antibody or antibody to CD4 (L3T4, 20 mg/ml) and then infectedwith
HIV-7SF-GFP pseudotyped with 89.6 Env. The cells were analyzed 3 days after infection. GFP+ (red) cells are overlaid on the total population (gray).
(C) Flow cytometric analysis of CEM-SS (CXCR4-expressing) or CEM-R5 (CXCR4- and CCR5-expressing) cells treated with 10 mg/ml AMD3100 or an equal
volume of DMSO and then infected with HIV-7SF-GFP pseudotyped with the dual-tropic HIV Env 92HT593. The cells were analyzed 3 days postinfection.
The percent GFP+ cells are shown in the numbers above each gate. Results are representative of two independent experiments.
(D–F) Flow cytometric analysis of cord-blood-derived CD133+ cells infected with HIV-7SF-GFP pseudotyped with the dual-tropic 89.6 (D) or 92HT (F) HIV Envs or
the R5-tropic YU-2 HIV env (E) in the presence and absence of 20 mMmaraviroc (R5-blocking) or 10 mg/ml AMD3100 (X4-blocking). The cells were analyzed 3 days
after infection. GFP+ cells (red) are overlaid on the total population (gray).
(G) Flow cytometric analysis of CD133+ UCB cells expanded 4–7 days in STIFmedia and then stained for the indicated cell surfacemarkers. Samples stained with
isotype control antibodies for CD133 and CD34 (top) or with antibodies to CD133 and CD34 but isotype control antibodies for CD4, CXCR4, and CCR5 (middle)
were included to determine gating. Numbers indicate the percent of cells falling within each gate.
(H) Summary graph showing percent of total CD133+CD34High cells that express both of the indicated receptors for three independent experiments; mean and
standard deviation (error bars) are shown. *p < 0.03, paired t test. See also Figure S2.
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Figure 5. Infection of Multipotent Cells Requires CXCR4
(A and B) Colony formation by cord-blood-derived HSPCs treated with 20 mM
maraviroc (A), 10 mg/ml AMD3100 (B), or an equal volume of DMSO, infected
with HIV-7SF-GFP pseudotyped with the dual-tropic HIV Env 89.6 and purified
by FACS. Two blinded counters analyzed the colonies 14–18 days after plating
in methylcellulose medium. Data are represented as number of colonies per
100 cells plated. The mean of the two scorers’ counts is shown.
(C and D) Colony formation by CD133+ UCB mock-infected in the presence of
20 mM maraviroc (C) or 10 mg/ml AMD3100 (D) or an equal volume of DMSO
and plated in methylcellulose 3 days after exposure. Colonies were scored
after 2 weeks by two blinded counters. The mean of the two scorers’ counts
is shown. (Erythroid, CFU-E; myeloid, CFU-GM; or multilineage, CFU-GEMM.)
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CXCR4-Tropic HIV Infects Hematopoietic Stem CellsIL-2Rgnull mice. In all, 13 animals were injected with infected
CD133+ cells and 4 were injected with mock-infected, unsorted
HSPCs. We used a population of mixed GFP+ and GFP cells for
two reasons: first, to minimize loss of infected cells that would
occur with more stringent purification; and second, to enable
us to distinguish between mice that specifically failed to engraft
infected (GFP+) cells and those that failed to engraft at all due to
technical error.
Because the HIV genome we used was not cytotoxic and
expressed GFP from a constitutively active promoter, we were
able to detect infected, mature peripheral blood cells that were
the progeny of the originally infected HSPCs. The use of this
construct thus enabled us to evaluate the developmental poten-
tial of all infected HSPCs, whereas we have previously shown
that when HSPCs are infected with replication-competent HIV,
the actively infected cells die rapidly (Carter et al., 2010).
Beginning 4 weeks after transplantation and continuing
monthly for 20 weeks after transplantation, peripheral blood
was collected from the mice and analyzed for GFP expression
by flow cytometry. Over time, we detected human cells
(HuCD45+MuCD45) in the periphery of all four mice that
received mock-infected transplants (animals 1–4 in Table 1
and Figure S3 and animals 1 and 2 in Figure S4). In addition,
we detected human cells in 7 of 13 mice that received infected
HPC transplants (animals 5–11 in Table 1 and Figure S4, animalsCell Ho5–10 in Figure 6B, and animal 11 in Figure S2). Of the mice that
engrafted, 71% (5 out of 7) had GFP+ cells, indicating successful
engraftment of cells infected with an HXB-Env-bearing virus
(animals 5–9 in Table 1 and Figures 6B and S4). Two of the seven
mice engrafted human cells that were all GFP (animals 10 and
11 in Table 1 and Figures 6B, S3, and S4). An example of one
of the six mice that failed to engraft human cells is also shown
(animal 12 in Figure 6B, see also animals 12–17 in Table 1).
Although animals 5–11 received both GFP+ and GFP human
cells, several animals (animals 5–7, 10, and 11) engrafted only
GFP+ or only GFP human cells. This is because only a small
fraction of the transplanted cells have the capacity to engraft in
the mouse, and these few cells account for all of the human cells
found in the peripheral blood. Because so few cells actually
engraft, it is not surprising that in some mice all of the engrafting
cells were GFP+ or all were GFP.
Although the frequency of human cells varied widely in the
engrafted mice (0.1%–9.6% human leukocytes, Table 1 and
Figures 6B and S3), all mice that engrafted with infected human
cells had GFP+ lymphoid (CD3+ and/or CD19+) and GFP+
myeloid (CD33+) cells in the periphery for at least 20 weeks after
transplantation. In all cases, the frequency of GFP+ human cells
in the peripheral blood increased after 8–10 weeks posttrans-
plant (Figure S4). As only HSCs can maintain multilineage recon-
stitution for more than 4–6 weeks in vivo, the increasing
frequency of GFP+ cells at later time points clearly demonstrates
that infected HSCs have engrafted.
For both GFP+ and GFP engraftments, T lymphocytes (CD3+)
were slow to appear in peripheral blood, consistent with prior
reports that human thymopoiesis is inefficient in NOD/SCID/
IL-2Rgnull mice after stem cell transplantation (Lan et al., 2006).
For example, by 20 weeks animal 9 clearly had GFP+CD3+ cells,
whereas these cells were not apparent at an early time point
(compare Figure 6C, 20 week time point for animal 9 with
16 week time point shown in Figure 6B). Additionally, animal 6
was sacrificed 26 weeks after transplantation, and the tissues
were examined for T cell chimerism. As shown in Figure 6D,
human CD3+ cells were present in both bone marrow and
spleen. Thus, T cells were clearly present in at least 2 of 5
mice that stably engrafted stem cells targeted by HIV.
DISCUSSION
The identification and eradication of long-lived cellular reservoirs
is necessary to cure HIV and eliminate the need for lifelong
therapy. We have previously demonstrated that HIV can infect
multipotent HSPCs, establishing both active and latent infec-
tions (Carter et al., 2010). Here we demonstrate that, similarly
to infection of T cells, infection of multipotent HSPCs depends
on CD4. However, based on the panel of Envs we tested, robust
infection of primitive HSPCs capable of generating multilineage
colonies in soft agar only occurs with CXCR4- or dual-tropic
viruses. Blockade of CXCR4 dramatically reduced infection of
multipotent hematopoietic cells by dual-tropic HIVs. In contrast,
the R5-tropic HIVs we tested had onlyminimal infectivity in multi-
potent HSPCs, and blockade of CCR5 had no effect on infection
of multipotent cells by dual-tropic HIVs.
The simplest explanation for the inability of CCR5-tropic
viruses to infect multipotent HSPCs is that CCR5 is notst & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevier Inc. 229
sp
le
en
bo
ne
m
ar
ro
w
Hu CD45
G
FP
CD33 CD3 CD19
82
6.9
0.1
0.3
7.4
1.496
00 0 0 0 0
0 0 0
0
0 0 0
0
84 89
4.4
4.4
0.1
78
0.2 2.66.8
9.6
97 46 52 91 6.1
3.0
1.9 1.10.8 1.62.7
97 0.9 8513
100 100
3.0 3.0
16
100
C
C
6
6
D
B
Hu CD45 CD33 CD3 CD19
M
u
C
D
45
G
FP
6
5
9
8
7
0.1
22 76
2.20
98 0
02.2
15
02.2
83
1.4
7.7 92
00.5
99 0.1
00.5
95 4.9
00.5
0.4
44 55
1.20
99 0
01.2
81 18
01.2
9.6
2.1 14
6914
16 0
084
15 1.1
8.875
0.5
12 35
3617
47 0
053
42 3.5
2.252
1.4
0 0
8020
0 0
0100
0 0
1189
0.0
0 0
0100
0 0
0100
0 0
0100
12
10
A
FS
C
Pre-Sort Enriched
2.4 49.0
GFP
M
u
C
D
45
G
FP
0.4
56 16
28 0.8
Mouse 9
20 weeks
Hu CD45 CD3
C
M
u
C
D
45
Figure 6. CXCR4-Tropic HIV Can Infect HSCs that Stably Engraft and Generate Multiple Lineages in NOD/SCID IL-2gnull Mice
(A) Upper panel, schematic of HIV-7SF-GFP and HXB envelope plasmid used to construct virus used in lower panel. Lower panel, flow cytometric analysis of
cord-blood-derived CD133+ HPCs infected with HIV-7SF-GFP pseudotyped with HXB Env after 3 days in culture. Cells in the right panel were sorted for GFP
positivity.
(B) Flow cytometric analysis of peripheral blood from transplantedmice 16–18weeks posttransplant. Leukocytes that were positive for humanCD45 and negative
for mouse CD45 were gated in the left panels. The right panels show staining of the indicated markers within this subpopulation. (CD33, myeloid; CD3, T cell;
CD19, B cell.)
(C) Flow cytometric analysis of peripheral blood cells harvested 20 weeks posttransplantation in animal 9.
(D) Flow cytometric analysis of bone marrow and spleen from animal 6 after 26 weeks. (C: untreated control animal.) See also Figure S3.
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CXCR4-Tropic HIV Infects Hematopoietic Stem Cellsexpressed at high enough levels to support infection. An alterna-
tive hypothesis is that engagement of R5-tropic Envs with
the CCR5 chemokine receptor affects the ability of multipotent
HSPCs to form colonies or is toxic to the cells. This hypothesis
is less likely because dual-tropic HIVs able to bind both
CXCR4 and CCR5 can infect cells with a multipotent phenotype.
In addition, we have detected minimal CCR5 expression or
signaling in response to CCR5 ligands on human CD34+
CD133+ cells.
HIV infection of multipotent HSPCs could lead to the presence
of viral genomes in multiple hematopoietic lineages. However,
HIV is primarily detected in myeloid and T cells, but not in B cells.
This apparent enigma may be explained by the fact that active230 Cell Host & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevierinfection of HSPCs leads to the upregulation of markers of
apoptosis and rapid depletion of infected cells from the culture
(Carter et al., 2010). Thus, the lack of evidence for HIV genomes
in B cells in infected people may be due to the fact that active
HIV infection kills early HSPCs, preventing the development of
infected cells in some lineages (Carter et al., 2010). Latent infec-
tion can also occur in HSPCs, but induction of differentiationmay
induce viral activation and subsequent cell death (Carter et al.,
2010).
We have also determined that HIV infects HSCs that are
capable of stable, multilineage engraftment in irradiated NOD/
SCID IL-2Rgnull mice. All of the mice that were successfully
transplanted with infected HSPCs demonstrated multilineageInc.
Table 1. Summary of Murine Xenotransplantation Results
Animal
Number of Cells
Transplanted Condition
% Human
Leukocytes
% of Human Leukocytes
that are GFP+
% of GFP+ Human Leukocytes that are:
Myeloid B cells T cells
1 50,000 Mock 0.6 0.0 - - -
2 50,000 Mock 0.1 0.0 - - -
3 100,000 Mock 0.1 0.0 - - -
4 150,000 Mock 0.1 0.0 - - -
5 50,000 7SF-GFP/HXB 0.1 98 16 78 0.0
6 50,000 7SF-GFP/HXB 1.4 100 4.9 92 0.1a
7 100,000 7SF-GFP/HXB 0.4 99 19 56 0.0
8 150,000 7SF-GFP/HXB 9.6 16 6.9 88 0.0
9 150,000 7SF-GFP/HXB 0.5 46 7.7 77 0.0b
10 100,000 7SF-GFP/HXB 1.4 0.0 - - -
11 100,000 7SF-GFP/HXB 0.6 0.0 - - -
12–17 150,000 7SF-GFP/HXB
(No engraftment)
0.0–0.03 0.0 - - -
Animals 1–4 were injected with mock-infected HPCs and successfully engrafted. Animals 5–11 were injected with virus-treated HPCs and were
successfully engrafted with human cells. Animals 12–17 were injected with virus-treated HPCs but did not successfully engraft. Percents of human
and GFP+ cells are percents of total peripheral blood leukocytes at 14–18 weeks after transplant.
a T cells present at 20 week time point (Figure 6C).
b T cells present in bone marrow (Figure 6D). See also Figure S4.
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significant implications for viral persistence because HSCs are
capable of long-term self-renewal in vivo. Thus, latently infected
HSCs would persist indefinitely, forming a long-term viral reser-
voir. Additionally, based on our prior results (Carter et al., 2010),
active infection can trigger cell death in multipotent HSPCs. If
a sufficient number of HSPCs were infected, the subsequent
death of these cells could disrupt the entire hematopoietic
cascade. Over many years, this disruption could impact the
function of the bone marrow. Unfortunately, the toxicity of
wild-type HIV precluded us from generating sufficient numbers
of infected cells to test whether wild-type virus from patient
samples infects cells in vivo that have the capacity to engraft.
The experiments presented here were only possible with the
use of replication-defective HIV constructs that do not express
additional cytotoxic HIV proteins following integration.
The findings in this study appear to conflict with previous
reports indicating that HSCs are resistant to infection with
HIV-1 as well as with lentiviral constructs pseudotyped with
HIV Envs (Shen et al., 1999; Weichold et al., 1998; Zhang et al.,
2007). The mechanism by which HIV-1 infection of HSCs is
purported to be blocked has been inconsistent: one study found
that the block was solely at the level of entry due to insufficient
expression of viral receptors and that VSVG-pseudotyped viral
particles could efficiently infect HSCs (Shen et al., 1999),
whereas another group found that there was a postentry block
to infection mediated by p21 (Zhang et al., 2007). The apparent
difference between our findings and those of previous groups
can be explained by low rates of infection (typically less than
2%) that rapidly decline over time because of the cytoxicity of
the virus. Such infection rates are too low to yield detectable
infection with many of the non-flow-cytometric assays used in
previous studies, especially those that require that the cells beCell Hocultured for more than a couple days. The use of recently opti-
mized culture conditions for HSPCs (Zhang et al., 2008) has
allowed us to increase infection rates in these cells due to
improved health of the cells. The previously described blocks
to infection likely contribute to the low infection rates that we
observe in HSPCs, but importantly, we show that these blocks
are not absolute and that X4-tropic HIVs can infect HSCs at
a low but significant rate.
In sum, we have shown that multipotent HSPCs and HSCs can
be infected by HIV and that this infection is primarily accom-
plished by CXCR4-tropic HIVs. The infection and destruction of
multipotent HSPCs may contribute to the more rapid decline in
CD4 counts associated with CXCR4-tropic HIV isolate emer-
gence. Alternatively, as infected HSCs could create an extremely
long-lived reservoir of virus, preferential infection of these cells
by CXCR4-tropic virus could provide a reservoir for the emer-
gence of CXCR4-tropic isolates late in disease: as other viral
reservoirs are depleted, CXCR4-tropic virus from the HSC and
HSPC reservoir could begin to predominate. In addition, our
demonstration that HIV can infect cells capable of stably engraft-
ing for months in the xenograft model indicates that HIV can
infect HSCs that are capable of self-renewal and, if the inte-
grated viral genome is latent, that it can be maintained and
even expanded by cell division.
Based on these data, there should be a renewed focus on
primitive hematopoietic progenitors as an important reservoir
for HIV that will require eradication to improve the treatment of
HIV-infected people. Our data suggesting that a subset of
HSCs and other primitive hematopoietic progenitors could
function as a latent reservoir for HIV raise the possibility that
combining HIV therapies with approaches to activate HSCs
might deplete this reservoir by triggering the apoptosis of
infected HSCs.st & Microbe 9, 223–234, March 17, 2011 ª2011 Elsevier Inc. 231
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Antibodies and Reagents
Antibodies to the following proteins were used for flow cytometry: CD34
(FITC-conjugated, BD Biosciences, Franklin Lakes, NJ), CD34 (APC-conju-
gated, Caltag, Burlingame, CA), CD34 (647-conjugated, eBioscience,
San Diego, CA), CD133 (PE-conjugated, Miltenyi Biotech, Bergisch
Gladbach, Germany), CD133 (biotin-conjugated with streptavidin-APC/Cy7,
eBioscience), Gag (FITC-conjugated, Beckman-Coulter, Brea, CA), Gag (PE-
conjugated, Beckman-Coulter), CD45 (APC/Cy7-conjugated, BD Biosci-
ences), CD33 (PE-conjugated, BD Biosciences), CD3 (PE/Cy5-conjugated,
BD Biosciences), CD19 (APC-conjugated, BD Biosciences), CD4 (BD Biosci-
ences), CXCR4 (PE/Cy7-conjugated, eBioscience), CCR5 (PE-conjugated,
eBioscience), mouse IgG (FITC-conjugated, Invitrogen, Carlsbad, CA). For
receptor blocking experiments, functional grade antibody against CD4 was
used (clone L3T4, eBioscience).
The env gene expression plasmid pcDNA-89.6env was created as
described (Carter et al., 2010). pcDNA-94UGenv was created by digesting
p94UG114.1.6 with XbaI and SmaI. The resulting 3021-nucleotide fragment
was then ligated to pcDNA3.1 (+), which had been digested with ApaI, blunted
by Klenow treatment, and digested with XbaI. We created the env gene
expression plasmid pEBB-NLenv by digesting pNL4-3 with SalI and NotI
and blunting the resulting fragment by Klenow treatment. The resulting frag-
ment was then ligated into pEBB that had been digested with NotI and blunted
by Klenow treatment.
Cell Culture
We obtained pre-existing umbilical cord blood (UCB) lacking subject identi-
fiers after scheduled cesarean section procedures. We obtained fresh
whole-bone-marrow (BM) aspirates from a commercial source (AllCells Ltd.,
Emeryville, CA). We prepared BM and UCB mononuclear cells (MNCs) by
Ficoll-Paque density separation (GE Healthcare, Little Chalfont, England)
according to the manufacturer’s instructions. UCB-MNCs were frequently
cryopreserved in 10% DMSO in FBS. BM-MNCs were always used fresh.
We prepared CD34+ or CD133+ cells from adherence-depleted mononuclear
cells with commercially available kits (positive selection MACS, Miltenyi
Biotech). After isolation we maintained HSPCs in STIF medium (StemSpan
or Stemline II medium supplemented with 100 ng/ml SCF, 100 ng/ml TPO,
100 ng/ml IGFBP-2, and 100 ng/ml Flt3-L) (Zhang et al., 2008).
We conducted methylcellulose colony-forming assays according to the
manufacturer’s recommendation (Methocult H4034, StemCell Technologies,
Vancouver, British Columbia, Canada). Colonies were scored based on
morphology using an inverted brightfield microscope at 403 or 1003 magni-
fication. CFU-GEMM morphology was verified at high power (2003). GFP
expression was analyzed on an inverted epifluorescent microscope.
HIV Preparation
We prepared infectious supernatants by transfection of proviral plasmids into
293T cells using polyethylenimine. For pseudotyped viruses, we concentrated
supernatants with high-molecular-weight polyethylene glycol precipitation
(Kohno et al., 2002). Pellets were resuspended in 1/5 to 1/10 the original
volume of StemSpanmedium and stored at80C. Virus infectivity was deter-
mined by infection of CEM-SS or CEM-R5 cells under identical conditions. moi
were calculated by applying the percent of infected CEM-SS cells to the
formula moi = Ln (1p) where p is the proportion of cells infected. We con-
ducted HIV infections with a standard spin infection technique for primary cells
(1048.63 g for 2 hr at room temperature) or by incubating the cells with virus at
37C for 2 hr.
Flow Cytometry
We stained cells in FACS buffer (2% FBS, 1% human serum, 2 mM HEPES,
0.025% NaN3/PBS) for 10–20 min on ice and washed and fixed them in 2%
paraformaldehyde/PBS. For intracellular Gag staining, we then incubated
the cells for 5 min in 0.1% Triton X-100 in PBS at 25C. We incubated washed
cells with anti-Gag antibody in FACS buffer for 30 min on ice. We analyzed the
cells on a FACScan or FACSCanto flow cytometer. We excluded dead cells
using 7AAD.232 Cell Host & Microbe 9, 223–234, March 17, 2011 ª2011 ElsevierFor analysis of murine peripheral blood, we lysed erythrocytes with IO Test 3
lysis buffer (Beckman-Coulter), and we stained leukocytes as described
above. We analyzed cells on a FACSCantoII analyzer. We excluded dead cells
from analysis by DAPI uptake and we excluded cell doublets using FSC-A/
FSC-H ratio.
We sorted cells with a FACSVantage SE or FACSAria cytometer (BD Biosci-
ences). For high-purity sorting, we used normal-R mode with a 1.0 sorted drop
envelope. For cell enrichment, we sorted cells in enrich mode with a 1.0 sorted
drop envelope.
For the calcium flux assay, cells were suspended in cell-loading media
(RPMI with 2% FBS and 25 mM HEPES) and loaded with 1.5 mM Indo-1 AM.
Cells were incubated at 37C for 45 min, then washed twice and resuspended
in FACS buffer. Surface staining was conducted as described above.
Following surface stain, cells were resuspended in cell-loading media and
equilibrated at 37C for 30–60min prior to analysis. EGTAwas added 1 hr prior
to analysis. Samples were analyzed using a FACSDiVa cyotmeter (BD Biosci-
ences). For the acid wash assay, cells were incubated in pH 2.7 glycine buffer
for 1 min, then washed with 9ml PBS and stained as above except that serum-
free buffer (PBS + 0.1% BSA) was used.
Mice
Nonobese diabetic severe combined immunodeficiency mice lacking the
interleukin-2 gamma receptor (NOD/SCID IL-2Rnull mice, strain NOD.CB17-
Prkdcscid Il2rgtm1Wjl/Szj, Jackson Laboratory, Bar Harbor, ME) were main-
tained at the University of Michigan by the Unit for Laboratory Animal Medi-
cine. All experiments were conducted in accordance with research protocols
approved by the University Committee on the Use and Care of Animals.
Mouse Transplantation
We cultured cord-blood-derived CD133+ cells for 4 days in STIF medium to
expand HSCs prior to infection. We then infected the cells with HIV-7SF-
GFP pseudotyped with HXB2 Env. After 3 days, we sorted GFP-positive cells,
rested them overnight in STIF medium, and then transplanted them into suble-
thally irradiated mice (340cGy). We used a Hamilton syringe fitted with a 27 G
needle to inject 25 ml of cells in PBS into the femur. We gave the transplanted
mice antibiotic water (1.1 gl neomycin and 0.121 gl polymyxin B).
Isolation of CD34+ Cells from HIV-infected Donors
HIV+ individuals were recruited from the University of Michigan HIV/AIDS
Treatment Program Outpatient Clinic. The human subjects protocol was
approved by the Institutional Review Board and General Clinical Research
Center and, as outlined in the protocol, all subjects signed informed consent
documents. Using sterile procedure, a Jamshidi needle was used to aspirate
1 ml of marrow aspirate from the posterior iliac crest. The sample was evalu-
ated for spicules to ensure adequate quality, and then 10ml ofmarrow aspirate
was obtained in preservative free heparin. The subjects experienced no
adverse events from the procedure. The bone marrow mononuclear cells
were prepared by density separation using Ficoll-Paque (GE Healthcare)
according to the manufacturer’s instructions, and total mononuclear cells
were counted.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.chom.2011.02.005.
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